Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL2586203 | 0.92 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSC | |
| Histidine SCHEMBL27902238 | 0.92 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSC | |
| D-Histidine SCHEMBL11606906 | 0.92 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSC | |
| Histidine SCHEMBL2586200 | 0.92 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSC | |
| Histidine SCHEMBL9222981 | 0.91 | GSR (0.33) | ALOX15BLMPMP22KMT2A | |
| Histidine SCHEMBL9222976 | 0.91 | GSR (0.33) | ALOX15BLMPMP22KMT2A | |
| Histidine SCHEMBL5583260 | 0.90 | CYP3A4 (0.31) | CYP3A4SLC7A5CTSC | |
| Histidine SCHEMBL27501345 | 0.89 | ALOX15 (0.30) | ALOX15BLMPMP22KMT2A | |
| Histidine SCHEMBL10530307 | 0.88 | GRM8 (0.33) | — | |
| Histidine SCHEMBL10530318 | 0.88 | GRM8 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087083-B1 | SYSTEMIC DISCOVERY, MATURATION AND EXTENSION OF PEPTIDE BINDERS TO PROTEINS | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | claimed |
| US-10253302-B2 | Method for producing ordered protein lattice | CRYSALIN LTD. (GB) | 2019-04-09 | — | — | US | claimed |
| US-20190086411-A1 | SYSTEMATIC DISCOVERY, MATURATION AND EXTENSION OF PEPTIDE BINDERS TO PROTEINS | Roche Sequencing Solutions, Inc. | 2019-03-21 | — | — | US | claimed |
| US-10161938-B2 | Systematic discovery, maturation and extension of peptide binders to proteins | Roche Sequencing Solutions, Inc. (US) | 2018-12-25 | — | — | US | claimed |
| US-20150185216-A1 | SYSTEMIC DISCOVERY, MATURATION AND EXTENSION OF PEPTIDE BINDERS TO PROTEINS | ROCHE NIMBLEGEN INC. | 2015-07-02 | — | — | US | claimed |
| US-20080032340-A1 | Peptide motifs for binding avidin or neutravidin | UNIVERSITY OF ARIZONA (US) | 2008-02-07 | — | — | US | claimed |
| US-20070275416-A1 | Affinity marker for purification of proteins | GSF-FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE) | 2007-11-29 | — | — | US | claimed |
| US-7138253-B2 | Streptavidin-binding peptides and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2006-11-21 | — | — | US | claimed |
| CN-107835871-B | Methods and compositions for peptide cyclization and protease treatment | 豪夫迈·罗氏有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-10976317-B2 | Systematic discovery, maturation and extension of peptide binders to proteins | Roche Sequencing Solutions, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3087083-B1 | SYSTEMIC DISCOVERY, MATURATION AND EXTENSION OF PEPTIDE BINDERS TO PROTEINS | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | disclosed |
| EP-3286314-B1 | COW ANTIBODY SCAFFOLD POLYPEPTIDE METHOD AND COMPOSITION | HOFFMANN LA ROCHE (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-20190086411-A1 | SYSTEMATIC DISCOVERY, MATURATION AND EXTENSION OF PEPTIDE BINDERS TO PROTEINS | Roche Sequencing Solutions, Inc. | 2019-03-21 | — | — | US | disclosed |
| US-10161938-B2 | Systematic discovery, maturation and extension of peptide binders to proteins | Roche Sequencing Solutions, Inc. (US) | 2018-12-25 | — | — | US | disclosed |
| WO-2016170101-A1 | COW ANTIBODY SCAFFOLD POLYPEPTIDE METHOD AND COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-27 | — | — | WO | disclosed |
| US-20160312212-A1 | COW ANTIBODY SCAFFOLD POLYPEPTIDE METHOD AND COMPOSITION | Roche Sequencing Solutions, Inc. | 2016-10-27 | — | — | US | disclosed |
| WO-2015097077-A2 | SYSTEMIC DISCOVERY, MATURATION AND EXTENSION OF PEPTIDE BINDERS TO PROTEINS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-02 | — | — | WO | disclosed |
| US-20150185216-A1 | SYSTEMIC DISCOVERY, MATURATION AND EXTENSION OF PEPTIDE BINDERS TO PROTEINS | ROCHE NIMBLEGEN INC. | 2015-07-02 | — | — | US | disclosed |
| US-20080032340-A1 | Peptide motifs for binding avidin or neutravidin | UNIVERSITY OF ARIZONA (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070275416-A1 | Affinity marker for purification of proteins | GSF-FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312212-A1 | COW ANTIBODY SCAFFOLD POLYPEPTIDE METHOD AND COMPOSITION | NUP205, PIGS, CD68 | ALOX15 4842/4885BLM 4570/4885PMP22 578/4885 |
| US-20080032340-A1 | Peptide motifs for binding avidin or neutravidin | DBNL, CACYBP, YBX1 | ALOX15 4050/4885BLM 1951/4885PMP22 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.